| 6.45 -0.89 (-12.13%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.67 | 1-year : | 11.29 |
| Resists | First : | 8.27 | Second : | 9.67 |
| Pivot price | 3.87  |
|||
| Supports | First : | 4.36 | Second : | 1.95 |
| MAs | MA(5) : | 6.54 |
MA(20) : | 3.41 |
| MA(100) : | 2.57 |
MA(250) : | 2.69 |
|
| MACD | MACD : | 1.1 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 79.5 |
D(3) : | 81.9 |
| RSI | RSI(14): 78.7 |
|||
| 52-week | High : | 8.27 | Low : | 1.83 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IBRX ] has closed below upper band by 17.4%. Bollinger Bands are 963.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 7.88 - 7.92 | 7.92 - 7.95 |
| Low: | 6.36 - 6.4 | 6.4 - 6.43 |
| Close: | 6.39 - 6.45 | 6.45 - 6.5 |
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
Fri, 23 Jan 2026
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz - Stocktwits
Thu, 22 Jan 2026
A Look At ImmunityBio (IBRX) Valuation After FDA Anktiva Pathway And Saudi Approvals - simplywall.st
Thu, 22 Jan 2026
Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That” - Yahoo Finance
Wed, 21 Jan 2026
ImmunityBio (NASDAQ:IBRX) Shares Gap Down - Should You Sell? - MarketBeat
Wed, 21 Jan 2026
ImmunityBio rally causes $492M paper losses for short sellers - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 985 (M) |
| Shares Float | 336 (M) |
| Held by Insiders | 66.4 (%) |
| Held by Institutions | 14.8 (%) |
| Shares Short | 120,640 (K) |
| Shares Short P.Month | 88,550 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.53 |
| Profit Margin | 0 % |
| Operating Margin | -173.6 % |
| Return on Assets (ttm) | -36.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 425.1 % |
| Gross Profit (p.s.) | 0.08 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -0.25 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -320 (M) |
| Levered Free Cash Flow | -230 (M) |
| PE Ratio | -15.74 |
| PEG Ratio | 0 |
| Price to Book value | -12.17 |
| Price to Sales | 76.95 |
| Price to Cash Flow | -19.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|